Estrogen receptor 1. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Fulvestrant CHEMBL1358 |
Estrogen receptor alpha antagonist Antagonist Estrogen receptor degrader Degrader Small molecule |
✓ Both | 133 |
| Tamoxifen CHEMBL83 |
Estrogen receptor alpha modulator Modulator Small molecule |
✓ Both | 38 |
| Elacestrant CHEMBL4297509 |
Estrogen receptor alpha degrader Degrader Small molecule |
ChEMBL only | 30 |
| Giredestrant CHEMBL4650316 |
Estrogen receptor alpha degrader Degrader Small molecule |
✓ Both | 15 |
| Camizestrant CHEMBL4650365 |
Estrogen receptor alpha degrader Degrader Small molecule |
✓ Both | 13 |
| Estradiol CHEMBL135 |
Estrogen receptor alpha agonist Agonist Small molecule |
✓ Both | 11 |
| Estradiol valerate CHEMBL1511 |
Estrogen receptor alpha agonist Agonist Small molecule |
ChEMBL only | 3 |
| Estriol CHEMBL193482 |
Estrogen receptor modulator Modulator Small molecule |
✓ Both | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Breast cancer | 3 | Phase 3 |
| Ductal breast carcinoma in situ | 3 | Phase 3 |
| Estrogen-receptor positive breast cancer | 3 | Phase 3 |
| Endometrial cancer | 3 | Phase 2 |
| Atrophic Vaginitis | 2 | Phase 3 |
| Dysmenorrhea | 2 | Phase 3 |
| Hot flashes | 2 | Phase 3 |
| Infertility | 2 | Phase 3 |
| Turner syndrome | 2 | Phase 3 |
| Ovarian cancer | 2 | Phase 3 |
| Sexual dysfunction | 2 | Phase 3 |
| Cancer | 2 | Phase 2 |
| Duchenne muscular dystrophy | 1 | Phase 3 |
| Headache | 1 | Phase 3 |
| Stress urinary incontinence | 1 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
